Human epididymal secretory protein 4 (HE4) elevation has been studied as a crucial biomarker for malignant gynecological cancer, such us ovarian cancer (OC). However, there are conflicting reports regarding the optimal HE4 cut-off. Thus, the goal of this study was to develop an analytical approach to harmonize HE4 values obtained with different laboratory resources. To this regard, six highly qualified Italian laboratories, using different analytical platforms (Abbott Alinity I, Fujirebio Lumipulse G1200 and G600, Roche Cobas 601 and Abbott Architett), have joined this project. In the first step of our study, a common reference calibration curve (designed through progressive HE4 dilutions) was tested by all members attending the workshop. This first evaluation underlined the presence of analytical bias in different devices. Next, following bias correction, we started to analyze biomarkers values collected in a common database (1509 patients). A two-sided p-value < 0.05 was considered statistically significant. In post-menopausal women stratified between those with malignant gynecological diseases vs. non-malignant gynecological diseases and healthy women, dichotomous HE4 showed a significantly better accuracy than dichotomous Ca125 (AUC 0.81 vs. 0.74, p = 0.001 for age ≤ 60; AUC 0.78 vs. 0.72, p = 0.024 for age > 60). Still, in post-menopausal status, similar results were confirmed in patients with malignant gynecological diseases vs. patients with benign gynecological diseases, both under and over 60 years (AUC 0.79 vs. 0.73, p = 0.006; AUC 0.76 vs. 0.71, p = 0.036, respectively). Interestingly, in pre-menopausal status women over 40 years, HE4 showed a higher accuracy than Ca125 (AUC 0.73 vs. 0.66, p = 0.027), thus opening new perspective for the clinical management of fertile patients with malignant neoplasms, such as ovarian cancer. In summary, this model hinted at a new approach for identifying the optimal cut-off to align data detected with different HE4 diagnostic tools.

New Analytical Approach for the Alignment of Different {HE}4 Automated Immunometric Systems: An Italian Multicentric Study / Angeloni, Antonio; DE VITO, Corrado; Farina, Antonella; Terracciano, Daniela; Cennamo, Michele; Passerini, Rita; Bottari, Fabio; Schirinzi, Annalisa; Vettori, Roberto; Steffan, Agostino; Mais, Valerio; Coghe, Ferdinando; Della Corte, Luigi; Bifulco, Giuseppe; Baccolini, Valentina; Berardelli, Elena; Migliara, Giuseppe; Anastasi, Emanuela. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 11:7(2022), pp. 1-12. [10.3390/jcm11071994]

New Analytical Approach for the Alignment of Different {HE}4 Automated Immunometric Systems: An Italian Multicentric Study

Antonio Angeloni
Supervision
;
Corrado De Vito
Formal Analysis
;
Antonella Farina
Writing – Original Draft Preparation
;
Valentina Baccolini
Formal Analysis
;
Elena Berardelli
Validation
;
Giuseppe Migliara
Formal Analysis
;
Emanuela Anastasi
Writing – Original Draft Preparation
2022

Abstract

Human epididymal secretory protein 4 (HE4) elevation has been studied as a crucial biomarker for malignant gynecological cancer, such us ovarian cancer (OC). However, there are conflicting reports regarding the optimal HE4 cut-off. Thus, the goal of this study was to develop an analytical approach to harmonize HE4 values obtained with different laboratory resources. To this regard, six highly qualified Italian laboratories, using different analytical platforms (Abbott Alinity I, Fujirebio Lumipulse G1200 and G600, Roche Cobas 601 and Abbott Architett), have joined this project. In the first step of our study, a common reference calibration curve (designed through progressive HE4 dilutions) was tested by all members attending the workshop. This first evaluation underlined the presence of analytical bias in different devices. Next, following bias correction, we started to analyze biomarkers values collected in a common database (1509 patients). A two-sided p-value < 0.05 was considered statistically significant. In post-menopausal women stratified between those with malignant gynecological diseases vs. non-malignant gynecological diseases and healthy women, dichotomous HE4 showed a significantly better accuracy than dichotomous Ca125 (AUC 0.81 vs. 0.74, p = 0.001 for age ≤ 60; AUC 0.78 vs. 0.72, p = 0.024 for age > 60). Still, in post-menopausal status, similar results were confirmed in patients with malignant gynecological diseases vs. patients with benign gynecological diseases, both under and over 60 years (AUC 0.79 vs. 0.73, p = 0.006; AUC 0.76 vs. 0.71, p = 0.036, respectively). Interestingly, in pre-menopausal status women over 40 years, HE4 showed a higher accuracy than Ca125 (AUC 0.73 vs. 0.66, p = 0.027), thus opening new perspective for the clinical management of fertile patients with malignant neoplasms, such as ovarian cancer. In summary, this model hinted at a new approach for identifying the optimal cut-off to align data detected with different HE4 diagnostic tools.
2022
biomarkers; multicentric study; ovarian cancer; HE4
01 Pubblicazione su rivista::01a Articolo in rivista
New Analytical Approach for the Alignment of Different {HE}4 Automated Immunometric Systems: An Italian Multicentric Study / Angeloni, Antonio; DE VITO, Corrado; Farina, Antonella; Terracciano, Daniela; Cennamo, Michele; Passerini, Rita; Bottari, Fabio; Schirinzi, Annalisa; Vettori, Roberto; Steffan, Agostino; Mais, Valerio; Coghe, Ferdinando; Della Corte, Luigi; Bifulco, Giuseppe; Baccolini, Valentina; Berardelli, Elena; Migliara, Giuseppe; Anastasi, Emanuela. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 11:7(2022), pp. 1-12. [10.3390/jcm11071994]
File allegati a questo prodotto
File Dimensione Formato  
Angeloni_New-Analytical_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1627866
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact